5 recruiting, 4 completed, 1 active not recruiting, 1 available. 7 Phase 3, 3 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Recruiting 4, Active not recruiting 1, Completed 1, Withdrawn 1 |
| Phase 4 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Vedolizumab IV: new trials by email Literature Review of Vedolizumab IV trials Research Report on Vedolizumab IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting Vedolizumab IV, Vedolizumab SC - Ulcerative Colitis, Crohn's Disease | Phase 4 | Recruiting | Takeda | 200 | 2025-03-27 | 2026-10-28 |
| A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Vedolizumab IV, Vedolizumab SC - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 70 | 2025-01-22 | 2026-08-03 |
| A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease Vedolizumab IV, Placebo - Crohn's Disease | Phase 3 | Recruiting | Takeda | 408 | 2023-06-16 | 2025-11-05 |
| A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) Vedolizumab IV, No Intervention - Ulcerative Colitis, Crohn's Disease | Phase 3 | Recruiting | Takeda | 240 | 2023-05-16 | 2026-05-07 |
| A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) Vedolizumab IV - Crohn's Disease (CD) | Phase 3 | Recruiting | Takeda | 120 | 2022-02-10 | 2026-05-05 |
| A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease Vedolizumab IV - Ulcerative Colitis, Crohn Disease | Phase 4 | Completed | Takeda | 150 | 2021-12-08 | 2025-02-12 |
| A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis Mirikizumab IV, Mirikizumab SC, Vedolizumab IV - Ulcerative Colitis | Phase 3 | Withdrawn | Eli Lilly and Company | 2021-04-20 | 2021-05-06 | |
| Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis Vedolizumab IV, Placebo - Moderately to Severely Active Ulcerative Colitis | Phase 3 | Active not recruiting | Takeda | 392 | 2017-08-03 | 2026-05-22 |
| Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease. Vedolizumab IV, Placebo - Crohn's Disease | Phase 3 | Completed | Takeda | 215 | 2017-08-03 | 2023-03-01 |
| Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis Vedolizumab IV - Colitis, Ulcerative | Phase 4 | Completed | Takeda | 278 | 2017-03-29 | 2023-07-28 |
| Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration Vedolizumab SC, Vedolizumab IV - Healthy | Phase 1 | Completed | Takeda | 48 | 2014-06-01 | 2017-02-01 |
| Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA Vedolizumab IV - Crohn's Disease, Ulcerative Colitis | Available | Takeda | 2026-02-27 |
Crohn Disease (8) · Colitis, Ulcerative (7)
Takeda (11) · Eli Lilly and Company (1)
United States (6) · China (5) · Belgium (3) · Canada (3) · Italy (3) · Japan (3) · Poland (3) · South Korea (3) · Spain (3) · United Kingdom (3) · Australia (2) · Croatia (2) · Czechia (2) · Greece (2) · Hungary (2)
2023 (3), 2014 (1), 2019 (1)